WeLeader Biomedical Co

WeLeader Biomedical Co Intangible Assets

The Intangible Assets of WeLeader Biomedical Co (7713.TWO) as of Oct 21, 2026 is 4.06 M TWD. In the previous year, Intangible Assets was 3.88 M TWD — a change of 4.64% (higher).

Intangible Assets

4.06 MTWD

YoY

4.64%

Last updated:

Intangible Assets of WeLeader Biomedical Co is 2024 4.06 M TWD. Intangible Assets of WeLeader Biomedical Co was 2023 3.88 M TWD. It decreases by 4.64% higher compared to the previous year.

The WeLeader Biomedical Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2020
6.85 M TWD
Jan 1, 2021
6.13 M TWD
Jan 1, 2022
5.74 M TWD
Jan 1, 2023
3.88 M TWD
Jan 1, 2024
4.06 M TWD
The WeLeader Biomedical Co Intangible Assets history
YEARIntangible AssetsYoY
4.06 MTWD+4.64%
3.88 MTWD-32.40%
5.74 MTWD-6.47%
6.13 MTWD-10.50%
6.85 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

Intangible Assets of WeLeader Biomedical Co is 4.06 M TWD in 2024.

Intangible Assets of WeLeader Biomedical Co changed from 3.88 M TWD to 4.06 M TWD, representing a 4.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's WeLeader Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — WeLeader Biomedical Co

All Key Metrics — WeLeader Biomedical Co